S-1/A: NovaBay Pharmaceuticals Seeks $3.16 Million in Public Offering to Bolster Eyecare and Wound Care Business

NovaBay Pharmaceuticals aims to raise capital through a public offering of common stock and warrants to support its eyecare and wound care product lines, including Avenova Spray.

Summary

• NovaBay Pharmaceuticals is conducting a public offering to sell up to 1,521,739 shares of common stock, Series F-1 warrants, and Series F-2 warrants, with a combined assumed price of $2.30 per share and accompanying warrants.
• The company is also offering pre-funded warrants as an alternative to common stock for purchasers who would exceed ownership limits.
• The offering aims to raise approximately $3.16 million, with potential for $3.68 million if the underwriter's option is fully exercised.
• Net proceeds will be used for working capital, general corporate purposes, and to redeem $561,700 of outstanding Secured Convertible Notes.
• NovaBay specializes in scientifically-created eyecare and wound care products, including Avenova Spray and NeutroPhase/PhaseOne.
• Preliminary Q2 2024 net revenue is estimated at $2.4 million, with $5.0 million for the first six months of 2024.
• Cash and cash equivalents as of June 30, 2024, are estimated at $0.8 million, with net cash used in continuing operations in Q2 2024 at $1.1 million.
• The company has a history of operating losses and has disclosed substantial doubt about its ability to continue as a going concern.
• NovaBay is working to regain compliance with NYSE American listing standards after receiving deficiency notices regarding stockholders' equity.
• A 1-for-35 reverse stock split was completed on May 30, 2024, to address listing requirements.

Sentiment

Score: 4

Explanation: The document highlights both positive aspects, such as a loyal subscriber base and doctor recommendations, and significant negative aspects, including operating losses, going concern doubts, and the need for additional capital. The overall sentiment is cautiously negative due to the financial challenges, but there are some positive indicators in the business.

Positives

• Avenova Spray has strong support from ophthalmologists and optometrists, creating a doctor-recommended halo effect.
• The company has a loyal subscriber base, with 23% of all online sales from subscribers in 2023.
• Avenova Spray has an average 4.5-star rating across all online channels.
• The DERMAdoctor Divestiture streamlined the business by reducing cash burn and allowing focus on the core eyecare business.
• The company has a plan accepted by the NYSE American to regain compliance with listing standards by October 18, 2025.

Negatives

• The company has a history of operating losses and expects expenses to exceed revenues in 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's current cash resources are not sufficient to fund operations beyond the third quarter of 2024.
• The company faces intense competition in the eyecare market.
• Goodwill, intangible and other assets from the DERMAdoctor acquisition in 2021 have become fully impaired, which adversely impacted profitability in 2023 and 2022.

Risks

• The company requires additional capital to finance operations, which may not be available on acceptable terms.
• The company's future success depends on the successful commercialization of its products, particularly Avenova Spray.
• The company is dependent on third parties to manufacture, supply, and distribute its products.
• Significant disruptions of information technology systems or breaches of information security could adversely affect the business.
• Adverse U.S. or international economic and political conditions could negatively affect the business.
• The company may be subject to product liability claims if its products cause unexpected reactions.
• The price of the company's common stock may fluctuate substantially, resulting in losses to stockholders.
• The company may issue additional shares of common stock, diluting ownership interests and potentially depressing the market price.

Future Outlook

The company believes that the net proceeds from this offering, together with existing cash and cash equivalents, will meet its capital needs through the fourth quarter of 2024 and support continued commercialization efforts and be used for working capital and general corporate purposes.

Industry Context

NovaBay operates in the competitive eyecare and wound care markets, facing competition from large companies like Allergan and Shire, as well as over-the-counter products. The company emphasizes the distinct advantages of its products, such as Avenova Spray's gentle formulation and NeutroPhase/PhaseOne's lack of toxic chemicals.

Comparison to Industry Standards

• Avenova Spray competes with products like Restasis, Xiidra, eye wipes, baby shampoo, and soap in the eyecare market.
• NeutroPhase and PhaseOne compete with older, lower-priced wound cleansers like Vashe and Betadine Surgical Scrub.
• Unlike competitors, NovaBay emphasizes that NeutroPhase and PhaseOne solutions are made without toxic chemicals and are gentle, non-irritating, and non-sensitizing to skin and new tissue.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees face uncertainty due to the company's financial instability and potential cost reduction measures.
• Customers may be affected by potential disruptions in product supply or changes in business strategy.
• Suppliers and creditors face increased risk due to the company's financial challenges and potential need for restructuring.

Next Steps

• The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
• The company will redeem the outstanding principal amount of its Secured Convertible Notes, which is $561,700 as of the date of this prospectus.
• The company will be subject to quarterly monitoring for compliance with the NYSE American's listing standards.
• The company will continue to evaluate and pursue strategic transactions, including other divestitures.

Key Dates

Keywords

NovaBay Pharmaceuticals, Avenova Spray, Public Offering, Warrants, Eyecare, Wound Care, Financial Results, Reverse Stock Split, NYSE American, Compliance